Efficacy of a chewable tablet containing sarolaner, moxidectin and pyrantel for the treatment of generalised demodicosis in dogs.

Background: Demodicosis is common in dogs and is caused by proliferation of commensal Demodex canis mites.

Objective: To evaluate the efficacy of sarolaner in combination with moxidectin and pyrantel (SMP) for the treatment of generalised demodicosis in dogs.

Animals: One hundred and thirty dogs with generalised demodicosis.

Efficacy of a chewable tablet containing sarolaner, moxidectin, and pyrantel (Simparica Trio) in the treatment of sarcoptic mange caused by Sarcoptes scabiei mite infestations in dogs.

Background: Infestation with Sarcoptes scabiei in dogs is a debilitating disease if left untreated and is transmissible to humans. Two field studies were conducted to confirm the efficacy of orally administered sarolaner in combination with moxidectin and pyrantel (Simparica Trio) in the treatment of sarcoptic mange in dogs.

Methods: Client-owned dogs with S.

Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats.

Background: Frunevetmab, a felinized antinerve growth factor monoclonal antibody, effectively decreases osteoarthritis (OA) pain in cats.

Objective: To evaluate the efficacy of frunevetmab given at monthly intervals in a randomized, placebo-controlled, parallel-group, double-blind superiority study.

Animals: Two hundred seventy-five client-owned cats with naturally-occurring OA pain and associated mobility impairment and disability.

Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio) for the prevention of angiostrongylosis in dogs presented as veterinary patients.

Background: Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral combination of sarolaner, moxidectin and pyrantel (Simparica Trio) for the prevention of A. vasorum infection in dogs (prevention study).

Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea and tick infestations on dogs presented as veterinary patients in Europe.

Background: A novel chewable oral tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) has recently been developed to provide persistent protection against flea and tick infections for a month, treatment of hookworm and roundworm infections and prevention of heartworm and lungworm disease in dogs. Two field studies were conducted to evaluate the safety and efficacy of Simparica Trio™ against natural flea and tick infestations on dogs in Europe.

Methods: Dogs with natural flea or tick infestations were allocated randomly to treatment on Day 0 with either Simparica Trio™ tablets (flea study: n = 297; tick study: n = 189) to provide 1.